Search results for Biogen

<![CDATA[Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals ]]>

Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook

Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqemb...

Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets

In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help debt leverage ratios but also free up capacity to do ot...

Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building on an existing partnership with local drugmaker TJ Biop...

Why Biogen Is Paying $5.6B to Buy Apellis Pharma

Biogen’s Apellis Pharmaceuticals acquisition comes nearly two years after the drugmaker purchased immunology startup Human Immunology Biosciences. CEO Chris Viehbacher said Apellis...

Biogen links up with Alloy platform to boost ASO drug development

The agreement allows Biogen to apply the platform to advance antisense therapeutics against multiple undisclosed targets. Alloy will receive an upfront payment and is eligible for...

Biogen axes Denali-partnered Parkinson’s prospect after phase 2 flop

A phase 2b trial of Biogen and Denali Therapeutics’ Parkinson’s disease candidate has missed its primary endpoint, prompting the partners to end development in the idiopathic form...

Biogen pushing tau drug forward despite Alzheimer’s study failure

One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2...

This biotech firm has room to run, even as its drug royalties are set to shrink

Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will support its growth, per Piper Sandler.

Biogen advances Alzheimer’s tau program despite midphase miss

A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the Alzheimer’s disease trial failed to yield the hoped-for dose...

Best Healthcare Stocks to Buy in 2026

Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies.

Parkinson’s drug from Biogen, Denali comes up short

High-level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of P...

Beigene

Beigene Anonymous (not verified) Thu, 04/30/2026 - 14:18 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

Beigene

Beigene Anonymous (not verified) Mon, 05/25/2026 - 11:38 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B

Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune...

ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout

In Alzheimer’s, Bristol Myers sees big promise beyond amyloid

Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.

ImmunityBio acquiring U.S. rights to Tokyo strain of BCG

Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get

Apellis jumps as Biogen agrees $5.6 Billion acquisition, offering $41/share plus milestones, boosting rare-disease portfolio. Importance Rank: ...

Transforming neurodegenerative disease treatment

Discover how Cognition Therapeutics is redefining hope for Alzheimer’s and Dementia with Lewy bodies [JG1] with innovative, accessible therapies.

<![CDATA[Boehringer Ingelheim Expands Immunology Pipeline With Preclinical Antibody Licensing Deal]]>

Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antit...

Genomics inks partnership deal with Greywolf to assess gene datasets

Genomics inked a partnership deal with fellow U.K.-based biotech Greywolf Therapeutics to organize and evaluate ERAP enzymes and how they influence autoimmune disease risks.

HexemBio raises $10.4M for a stem cell rejuvenation therapy

The Berkeley biotech is backing a Nature-published approach that recreates the embryonic environment where blood stem cells first form, rather than reprogramming aged cells chemica...